Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 28;13(11):1470-1473.
doi: 10.1093/ecco-jcc/jjz084.

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature

Fabiënne G M Smeets  1 , Paulien R Liedorp  1   2 , Marjolein van der Poel  3 , Razvan L Miclea  4 , Ad A M Masclee  1 , Marieke Pierik  1
Affiliations
Review

Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature

Fabiënne G M Smeets et al. J Crohns Colitis. .

Abstract

Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.

Keywords: Crohn’s disease; Ustekinumab; lymphoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Upper gastrointestinal endoscopy demonstrating extensive oesophagitis with deep ulcers due to Crohn’s disease [CD] during treatment with vedolizumab.
Figure 2.
Figure 2.
Extensive para-aortic and para-iliac lymphadenopathy on abdominal computed tomography [CT] scan.
Figure 3.
Figure 3.
Extensive lymphadenopathy below the diaphragm with novel thoracic lymphadenopathy on positron emission tomography computed tomography [PET-CT] scan.
Figure 4.
Figure 4.
Extensive infiltrative intrapulmonary changes on low-dose positron emission tomography computed tomography [PET-CT].
Figure 5.
Figure 5.
Enlarged lymph node in the right axilla after two second-line GDP [gemcitabine, dexamethasone, cisplatin] treatments on computed tomography [CT] scan.
See this image and copyright information in PMC

References

    1. Jiménez-Pérez M, Olmedo-Martín RV, Amo-Trillo VM, González-Gande R. Inflammatory bowel disease: new therapeutic options in the post Anti-TNFα era. Curr Drug Metab 2017;18:666–79. - PubMed
    1. Toussirot E, Michel F, Béreau M, Binda D. Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement. Patient Prefer Adherence 2013;7:369–77. - PMC - PubMed
    1. MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2016;11:CD007572. - PMC - PubMed
    1. Feagan BG, Sandborn WJ, Gasink C, et al. ; UNITI–IM-UNITI Study Group Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016;375:1946–60. - PubMed
    1. Sandborn WJ, Rutgeerts P, Gasink C, et al. . Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy. Aliment Pharmacol Ther 2018;48:65–77. - PMC - PubMed

MeSH terms